ABC-1Homo sapiens (Human)Cancer cell line
Also known as: ABC1
Quick Overview
Human lung cancer cell line with EGFR mutations and genetic heterogeneity.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1066 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age | 47 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | HSRRB |
|---|---|
| Source ID | ACH-000528_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Pro278Ser (c.832C>T) | Unspecified | - | PubMed=24662767, PubMed=21602893 |
| MutationSimple | EGFR | p.Leu858Arg (c.2573T>G) | Unspecified | In 10% of cells | PubMed=31882684 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Cancer Res. 65:7276-7282(2005).
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Tabata M., Ueoka H., Tanimoto M.
In Vivo 19:717-721(2005).
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hirohashi S., Inazawa J., Imoto I.
Hum. Mol. Genet. 14:997-1007(2005).
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.
Fujisawa T.
Cancer Immunol. Immunother. 53:786-792(2004).
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
Clin. Cancer Res. 9:4705-4713(2003).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Establishment of a drug sensitivity panel using human lung cancer cell lines.
Kohara H., Harada M.
Acta Med. Okayama 53:67-75(1999).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.
Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.
Anticancer Drug Des. 8:417-428(1993).
Experimental model of human lung cancer, Part II. Heterotransplantation of human continuous cell lines from squamous cell carcinoma and adenocarcinoma of the lung.
Watanabe Y.
Okayama Igakkai Zasshi 97:701-712(1985).
Experimental model of human lung cancer, Part I. Establishment and characterization of new tissue culture cell lines from human squamous cell carcinoma and adenocarcinoma of the lung.
Watanabe Y.
Okayama Igakkai Zasshi 97:691-700(1985).
Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of heterotransplantation.
Ikeda H., Nakata Y., Ohnoshi T., Kimura I.
Nihon Haigan Gakkai 22:53-58(1982).